Abstract
Aim
Ceftobiprole, a broad-spectrum cephalosporin, could be used for post-operative treatment of bone implant-associated infections. The aim of the study is to evaluate the in vitro susceptibility of bacteria isolated from bone implant-associated infections to ceftobiprole.
Method
We conducted an in vitro, retrospective and comparative study between July 2013 to April 2017 including patients with bone implant-associated infections (prosthesis joint infection (PJI) and osteosynthesis material (OM)). To evaluate MIC distribution of ceftobiprole against Gram positive and Gram negative strains and to compare activity of ceftobiprole to vancomycin for Gram positive and ceftriaxone or ceftazidime for Gram negative strains, we tested all strains (stored in Cryobank storage system) for minimal inhibitory concentrations (MIC) determination by E-test bandelet for ceftobiprole and comparator antibiotics.
Results
We collected 63 Gram negative strains (57 Enterobateriaceae and 6 Pseudomonas aeruginosa), isolated from 25 patients with OM and 38 patients with PJI (23 hips and 15 knees), and 100 Gram positive strains (85 Staphylococcus sp, 8 E. faecalis, 7 Propionibacterium sp.) isolated from 38 patients with OM and 62 patients with PJI (33 hips, 28 knees, 1 shoulder).
A total of 61.4% of Enterobacteriaceae were susceptible both with ceftobiprole and ceftriaxone, 100% of P. aeruginosa were susceptible with ceftazidime and 83,3% with ceftobiptrole and finally 100% of Gram positive were susceptible both with ceftobiprole and vancomycin (susceptibility interpretation was based on EUCAST breakpoints)
Conclusions
Our results suggest that ceftobiprole has a good in vitro activity against strains isolated from bone implant-associated infections. It could be an effective alternative to vancomycin and ceftriaxone or ceftazidime in post-operative treatment but pharmacokinetics and pharmacodynamics studies must be performed in bone tissue.
